Archives of microbiology · 2026
Divergent mechanistic pathways of diarrheagenic bacterial infections at the host-microbiota interface: a review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bayode Michael Tosin, Olawale Oluwatoyosi Ezekiel, Olusola-Makinde Olubukola Olayemi
Аннотация
Bacterial diarrheal diseases continue to constitute a major burden on global public health, particularly within pediatric populations in low-resource settings. While clinically unified by the symptomology of diarrhea, the primary causative agents; Enterotoxigenic Escherichia coli (ETEC), Shigella species, Salmonella enterica, and Clostridioides difficile employ fundamentally distinct molecular strategies to subvert intestinal homeostasis. This review presents a comparative analysis of these ecosystem engineers, proposing that their pathogenicity is defined by their unique management of the host-microbiota metabolic and signaling conflict. We advance beyond the traditional host-pathogen dyad to explore a mechanistic triangle, integrating recent findings that the microbiota acts as a dynamic third player imposing colonization resistance via secondary bile acids and nutrient competition (proline), or conversely, providing metabolic fuel (formate, tetrathionate) for pathogen expansion. We synthesize advanced molecular insights from including the energetics of the Shigella T3SS sorting platform (Spa47); the multilayered "effector-immunity arms race" involving the Shigella effectors OspC1 and OspD3 in manipulating necroptosis; novel Salmonella T3SS-2 targets such as LMO4 and SteA-mediated ER contact sites; and the receptor diversity of C. difficile TcdB variants. Finally, we map these mechanisms to next-generation therapeutic vulnerabilities, highlighting the transition from broad-spectrum antibiotics to precision bacteriophage biocontrol (LPEK22, LPST94) and AI-discovered lysins (DeepLysin) as the future of intervention.